Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 25934 results found since Jan 2013.
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment-resistant, metastatic prostate cancer(mPC) models. B7H3 is a tumor-specific surface protein widely expressed in mPC, and PBD is a DNA cross-linking agent. B7H3 expression was necessary but not sufficient for B7H3-PBD-ADC responsiveness. RB1 deficiency and/or replication stress, characteristics of poor prognosis, conferred sensitivity and were associated with complete tumor regression in both neuroendocrine (NEPC) and androgen receptor positive(ARPC) prostate cancer models, even with low B7H3 l...
Source: Clinical Prostate Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Supreet Agarwal Lei Fang Kerry McGowen JuanJuan Yin Joel Bowman Anson T Ku Aian Neil Alilin Eva Corey Martine P Roudier Lawrence D True Ruth F Dumpit Ilsa Coleman John K Lee Peter S Nelson Brian J Capaldo Aida Mariani Clare E Hoover Ilya S Senatorov Micha Source Type: research
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study
CONCLUSIONS: An increasing proportion of patients received systemic treatment during the period 2010-18. However, less than 50% of patients in our study received systemic treatment. In accordance with updated guidelines, Docetaxel was introduced after 2015 with an increasing proportion of patients receiving systemic treatment as mHSPC. Further studies should address the disease course and treatment given to patients who do not receive systemic treatment.PMID:37725527 | DOI:10.1080/0284186X.2023.2257876
Source: Acta Oncologica - September 19, 2023 Category: Cancer & Oncology Authors: Anne Holck Stor ås Kaitlyn Tsuruda Sophie Dorothea Foss å Bettina Kulle Andreassen Source Type: research
Long-term follow-up results of multiparametric prostate MRI and the prognostic value of PI-RADS: a single-center retrospective cohort study
CONCLUSION: The PI-RADS category has a significant impact on patient management and provides important diagnostic and prognostic information. Higher initial PI-RADS categories are associated with decreased follow-up losses, a shorter time to PCa diagnosis, increased biopsy rates, a higher likelihood of developing cs-PCa during follow-up, and a worse PCa prognosis. Combining mPSAD with PI-RADS categories could enhance diagnostic stratification in the identification of cs-PCa.PMID:37724756 | DOI:10.4274/dir.2023.232414
Source: Diagnostic and Interventional Radiology - September 19, 2023 Category: Radiology Authors: Ömer Önder M üjdat Ayva Yasin Yara şır Volkan G ürler Mustafa Serta ç Yazıcı B ülent Akdoğan Ali Devrim Karaosmano ğlu Mu şturay Karçaaltıncaba Mustafa Nasuh Özmen Deniz Akata Source Type: research
Transcriptome Data Reveal Geographic Heterogeneity in Gene Expression in Patients with Prostate Cancer
CONCLUSIONS: This study suggests that geographic heterogeneity in PC incidence is associated with the expression levels of genes associated with amino acid metabolism, lipid metabolism, and ion channels.PMID:37724140 | PMC:PMC10505463 | DOI:10.52547/rbmb.12.1.92
Source: Mol Biol Cell - September 19, 2023 Category: Molecular Biology Authors: Yi Zheng Yang Wang Haitian He Zhuping Zou Huiling Lu Jinlong Li Jun Cai Kebing Wang Source Type: research
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
CONCLUSIONS: Our results suggest that GG 1 patients already show a low level of failure at a standard dose of 77 Gy, limiting the additional benefit of focal boosting. In contrast, patients with high-risk characteristics, especially GG 4 or 5, show a low 5-year DFS, while focal boosting might improve this substantially. This suggests that reaching a high focal boost dose may be particularly beneficial for these patients.PMID:37725026 | DOI:10.1016/j.ijrobp.2023.07.044
Source: Health Physics - September 19, 2023 Category: Physics Authors: Karol ína Menne Guricová Veerle Groen Floris Pos Evelyn Monninkhof Sjoerd G Elias Karin Haustermans Robert J Smeenk Jochem van der Voort van Zyp C édric Draulans Sofie Isebaert Petra J van Houdt Linda G W Kerkmeijer Uulke A van der Heide Source Type: research
Long-term follow-up results of multiparametric prostate MRI and the prognostic value of PI-RADS: a single-center retrospective cohort study
CONCLUSION: The PI-RADS category has a significant impact on patient management and provides important diagnostic and prognostic information. Higher initial PI-RADS categories are associated with decreased follow-up losses, a shorter time to PCa diagnosis, increased biopsy rates, a higher likelihood of developing cs-PCa during follow-up, and a worse PCa prognosis. Combining mPSAD with PI-RADS categories could enhance diagnostic stratification in the identification of cs-PCa.PMID:37724756 | DOI:10.4274/dir.2023.232414
Source: Diagnostic and Interventional Radiology : The Turkish Society of Radiology - September 19, 2023 Category: Radiology Authors: Ömer Önder M üjdat Ayva Yasin Yara şır Volkan G ürler Mustafa Serta ç Yazıcı B ülent Akdoğan Ali Devrim Karaosmano ğlu Mu şturay Karçaaltıncaba Mustafa Nasuh Özmen Deniz Akata Source Type: research
Transcriptome Data Reveal Geographic Heterogeneity in Gene Expression in Patients with Prostate Cancer
CONCLUSIONS: This study suggests that geographic heterogeneity in PC incidence is associated with the expression levels of genes associated with amino acid metabolism, lipid metabolism, and ion channels.PMID:37724140 | PMC:PMC10505463 | DOI:10.52547/rbmb.12.1.92
Source: Mol Biol Cell - September 19, 2023 Category: Molecular Biology Authors: Yi Zheng Yang Wang Haitian He Zhuping Zou Huiling Lu Jinlong Li Jun Cai Kebing Wang Source Type: research
Long-term follow-up results of multiparametric prostate MRI and the prognostic value of PI-RADS: a single-center retrospective cohort study
CONCLUSION: The PI-RADS category has a significant impact on patient management and provides important diagnostic and prognostic information. Higher initial PI-RADS categories are associated with decreased follow-up losses, a shorter time to PCa diagnosis, increased biopsy rates, a higher likelihood of developing cs-PCa during follow-up, and a worse PCa prognosis. Combining mPSAD with PI-RADS categories could enhance diagnostic stratification in the identification of cs-PCa.PMID:37724756 | DOI:10.4274/dir.2023.232414
Source: Diagnostic and Interventional Radiology - September 19, 2023 Category: Radiology Authors: Ömer Önder M üjdat Ayva Yasin Yara şır Volkan G ürler Mustafa Serta ç Yazıcı B ülent Akdoğan Ali Devrim Karaosmano ğlu Mu şturay Karçaaltıncaba Mustafa Nasuh Özmen Deniz Akata Source Type: research
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment-resistant, metastatic prostate cancer(mPC) models. B7H3 is a tumor-specific surface protein widely expressed in mPC, and PBD is a DNA cross-linking agent. B7H3 expression was necessary but not sufficient for B7H3-PBD-ADC responsiveness. RB1 deficiency and/or replication stress, characteristics of poor prognosis, conferred sensitivity and were associated with complete tumor regression in both neuroendocrine (NEPC) and androgen receptor positive(ARPC) prostate cancer models, even with low B7H3 l...
Source: Clinical Prostate Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Supreet Agarwal Lei Fang Kerry McGowen JuanJuan Yin Joel Bowman Anson T Ku Aian Neil Alilin Eva Corey Martine P Roudier Lawrence D True Ruth F Dumpit Ilsa Coleman John K Lee Peter S Nelson Brian J Capaldo Aida Mariani Clare E Hoover Ilya S Senatorov Micha Source Type: research
Antioxidative stress protein SRXN1 can be used as a radiotherapy prognostic marker for prostate cancer
To explore the mechanisms of radiotherapy resistance and search for prognostic biomarkers for prostate cancer.
Source: BMC Urology - September 19, 2023 Category: Urology & Nephrology Authors: Xing Wang, Jiandi Yu, Huali Wen, Junfeng Yan, Kun Peng and Haiyong Zhou Tags: Research Source Type: research
Perirenal Fascia - an Uncommon Site of Metastases in Prostate Cancer Detected on < sup > 68 < /sup > Ga-PSMA-11 PET/CT
We report a case of a 50-year-old man with biopsy-proven high-risk PCa in which multiple tracer avid perirenal fascia deposits were identified on 68Ga-PSMA-11 PET/CT, in addition to multi-focal prostatic primary, extensive nodal, and skeletal metastases. This case highlights that perirenal fascia is an uncommon metastatic site in PCa.PMID:37720882 | PMC:PMC10504131 | DOI:10.1007/s13139-023-00801-w
Source: Molecular Medicine - September 18, 2023 Category: Molecular Biology Authors: Kunal Ramesh Chandekar Swayamjeet Satapathy Sridhar Panaiyadiyan Rakesh Kumar Source Type: research
Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
CONCLUSION: Our research demonstrates a closely relationship among CD47 and the immunological microenvironment of prostate cancer, and blocking CD47 can promote macrophages to phagocytosis of prostate cancer cells. Therefore, CD47 may provide novel strategies for potential immunotherapy of prostate cancer.PMID:37719086 | PMC:PMC10505079 | DOI:10.1155/2023/2473075
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Qianqian Wang Chunxaing Feng Yuchun Chen Tianming Peng Yong Li Kunlin Wu Xiaoyong Pu Hanzhong Chen Jiumin Liu Source Type: research
